There are currently 42 ongoing clinical trials involving Lupus Nephritis
Of the 42 trials,19 trials are in Phase II
Furthermore, 11 trials are in Phase IV
The global pharmaceutical industry is steadily developing new drugs for Lupus Nephritis, an Immunology condition. The largest number of ongoing clinical trials for Lupus Nephritis is conducted in Asia-Pacific. Europe and North America are among some of the other prominent regions engaged in Lupus Nephritis-related drug trials.
University of Hong Kong: The leading ongoing Lupus Nephritis related clinical trial sponsor
University of Hong Kong is the top sponsor for Lupus Nephritis-related ongoing clinical trials.
Novartis AG, Johnson & Johnson, F. Hoffmann-La Roche Ltd, Postgraduate Institute of Medical Education and Research, and Bristol-Myers Squibb Co are among other notable clinical trial sponsors involved in Lupus Nephritis. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Lupus Nephritis
Tacrolimus (Modigraf, Prograf, Prograft), Belimumab (Benlysta), and Mycophenolate Mofetil (Cellcept) are among the key marketed drugs involving Lupus Nephritis.
Tacrolimus (Modigraf, Prograf, Prograft) is an immunosuppressive agent. It functions via the Calcineurin Inhibitor mechanism of action. Prograf is formulated as hard gelatin capsules, granules, powder for suspension for the oral route of administration, and injectable solution for the intravenous and intravascular route of administration. Prograf is used to treat prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, or heart transplants used concomitantly with adrenal corticosteroids, interstitial pneumonia associated with polymyositis/ dermatomyositis. Tacrolimus was first approved in 1993 and is marketed globally including the US, the UK, Australia, France, Germany, China and Japan by Astellas Pharma US Inc.
Belimumab (Benlysta) is a human IgG1 monoclonal antibody specific for soluble human B lymphocyte stimulator protein (BlyS), which acts as an immunosuppressant agent. It functions via Tumor Necrosis Factor Ligand Superfamily Member 13B Inhibitor mechanism of action. It is formulated as Lyophilized powder for solution and solution for the intravenous and subcutaneous route of administration. Benlysta is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity despite standard therapy, and for the treatment of systemic lupus erythematosus inadequately treated with existing treatments in pediatrics, as add-on therapy in patients with active, autoantibody-positive systemic lupus erythematosus with a high degree of disease activity in children of five years and older. Belimumab was first approved in 2011 and is marketed globally including the US, the UK, Australia, France, Germany, China, and Japan by GlaxoSmithKline LLC.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer
Contact the team or request a demo to find out how our data can drive your business forward